Stock A234690 GREEN CROSS WELLBEING CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials GREEN CROSS WellBeing Corporation

Equities

A234690

KR7234690006

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
10,180 KRW +0.79% Intraday chart for GREEN CROSS WellBeing Corporation -0.20% +25.22%
2022 GREEN CROSS WellBeing Corporation(KOSDAQ:A234690) dropped from S&P Global BMI Index CI
2020 GREEN CROSS WellBeing Corporation(KOSDAQ:A234690) added to S&P Global BMI Index CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 187,287 248,532 180,186 146,101 144,326
Enterprise Value (EV) 1 140,920 233,063 200,287 174,992 178,424
P/E ratio 26.3 x 163 x 26.9 x 18.3 x 21.4 x
Yield - - - - -
Capitalization / Revenue 2.8 x 3.29 x 1.98 x 1.33 x 1.2 x
EV / Revenue 2.11 x 3.08 x 2.2 x 1.59 x 1.48 x
EV / EBITDA 15.2 x 55.3 x 20.4 x 16 x 11.2 x
EV / FCF 42.2 x -11.7 x -4.55 x -28.9 x -30.8 x
FCF Yield 2.37% -8.55% -22% -3.46% -3.25%
Price to Book 2.25 x 2.99 x 2.04 x 1.52 x 1.44 x
Nbr of stocks (in thousands) 17,752 17,752 17,752 17,752 17,752
Reference price 2 10,550 14,000 10,150 8,230 8,130
Announcement Date 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 66,938 75,603 90,968 109,729 120,535
EBITDA 1 9,257 4,212 9,841 10,918 15,876
EBIT 1 7,624 2,317 7,772 8,396 10,457
Operating Margin 11.39% 3.06% 8.54% 7.65% 8.68%
Earnings before Tax (EBT) 1 7,324 1,502 8,134 9,353 8,249
Net income 1 5,699 1,529 6,703 8,001 6,748
Net margin 8.51% 2.02% 7.37% 7.29% 5.6%
EPS 2 400.5 86.14 377.6 450.7 380.0
Free Cash Flow 1 3,339 -19,936 -44,025 -6,062 -5,795
FCF margin 4.99% -26.37% -48.4% -5.52% -4.81%
FCF Conversion (EBITDA) 36.07% - - - -
FCF Conversion (Net income) 58.59% - - - -
Dividend per Share - - - - -
Announcement Date 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - 20,101 28,891 34,098
Net Cash position 1 46,366 15,469 - - -
Leverage (Debt/EBITDA) - - 2.043 x 2.646 x 2.148 x
Free Cash Flow 1 3,339 -19,936 -44,025 -6,062 -5,795
ROE (net income / shareholders' equity) 10.2% 1.84% 7.82% 8.68% 6.87%
ROA (Net income/ Total Assets) 6.54% 1.31% 3.83% 3.63% 4.26%
Assets 1 87,128 116,841 174,968 220,518 158,379
Book Value Per Share 2 4,685 4,680 4,974 5,417 5,648
Cash Flow per Share 2 688.0 1,331 494.0 149.0 90.20
Capex 1 1,121 22,328 42,874 7,447 941
Capex / Sales 1.67% 29.53% 47.13% 6.79% 0.78%
Announcement Date 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
GREEN CROSS WELLBEING CORPORATION Stock GREEN CROSS WellBeing Corporation
+25.22% 131M
CSL LIMITED Stock CSL Limited
-3.45% 87.17B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.97% 40.1B
UCB Stock UCB
+57.98% 25.12B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.82% 15.59B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-8.82% 12B
INCYTE CORPORATION Stock Incyte Corporation
-16.29% 11.8B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-41.58% 11.8B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.89% 8.81B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-10.53% 8.24B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A234690 Stock
  4. Financials GREEN CROSS WellBeing Corporation